Transforming growth factor-beta 3 relation with osteoporosis and osteoporotic fractures

Abstract

Background: The high socioeconomic impact of osteoporosis and osteoporotic fracture is due to their high mortality, morbidity, and disease-related costs. Nowadays, bone mineral density (BMD) is a comparatively expensive way to diagnose and follow up patients with osteoporosis. Transforming growth factor-beta 3 (TGF-beta 3) is a protein categorized into cytokines. Some previous in vitro studies showed TGF-beta 3 effects on osteocytes and bone formation. Therefore, we conducted this study to find if there is any significant relationship between TGF-3 and BMD results. Materials and Methods: This was an analytical cross-sectional study conducted in 2017. We included individuals who had been referred from their physicians to undergo BMD dual-energy X-ray absorptiometry. Blood samples were taken from 150 participants for measuring TGF-beta 3 with ELISA method. Results: The mean standard deviation of TGF-beta 3 serum level was 79 30.8 pg/ml (minimum 41 pg/ml and maximum 210 pg/ml). There was a statistically significant and direct proportional relationship between TGF-beta 3 and T-score as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture (P = 0.001) (Pearson's correlation = +0.95). Conclusion: There was a significant relationship between TGF-beta 3 serum level and BMD. TGF-beta 3 serum level may be used as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture.